.png)
_(1).png){kind=logo}
Perbandingan Efek Samping Lokal dengan Sistemik Pascavaksinasi COVID-19 Booster pada Anggota Paguyuban Pasundan yang Diberi Vaksin AstraZeneca
Abstract
Abstrak
Tujuan penelitian adalah untuk membandingkan efek samping terhadap vaksinasi booster COVID-19 menggunakan vaksin AstraZeneca serta membandingkan efek samping lokal dengan sistemik. Penelitian dilakukan di lingkungan Paguyuban Pasundan pada Februari 2022, model penelitian analitik observasional dengan pendekatan kohort prospektif menggunakan sampel data primer diambil dari google form sebagai media pengisian kuesioner dengan pengambilan sampel dilakukan secara acak, kemudian data dikumpulkan dan diproses dengan program Microsoft Excel dan SPSS versi 26,0. Jumlah subjek dalam penelitian ini 119 responden yang seluruhnya anggota Paguyuban Pasundan. Jenis vaksinasi kesatu dan kedua yang diterima responden adalah Sinovac, untuk vaksinasi ketiga adalah AstraZeneca. Efek samping yang timbul pada vaksinasi booster menggunakan vaksin AstraZeneca didominasi oleh efek samping lokal seperti nyeri di bahu tempat suntikan (56%) dan pegal tempat suntikan (56%), diikuti dengan efek samping sistemik seperti nyeri otot seluruh tubuh (28,5%), demam (27%), dan kepala pusing (25,2%). Hasil independen t-test terdapat nilai probabilitas sebesar 0,001 (<0,05), terdapat perbedaan signifikan efek samping lokal dengan sistemik. Disimpulkan bahwa efek samping lokal lebih sering dirasakan dibanding dengan efek samping sistemik.
Kata kunci: Booster, COVID-19, efek samping, vaksin
A Comparison of Local and Systemic Side Effects Post-Covid-19 Booster Vaccination on Paguyuban Pasundan Members who were Given the AstraZeneca Vaccine
Abstract
This study aimed to comparison the side effects of the COVID-19 booster vaccination using the AstraZeneca vaccine, and to compare the local and systemic side effects. This study was accomplished in the Paguyuban Pasundan environment in February 2022. The research model was observational analytic with a prospective cohort approach using primary data samples taken from Google Form as a medium for filling out questionnaires with a simple random sampling. Afterwards, the data was gathered and processed using Microsoft Excel and SPSS version 26.0. The respondents in this study were 119 persons who were all members of the Paguyuban Pasundan. The vaccines 1 and 2 received by the respondents were Sinovac, the vaccines 3 were AstraZeneca. The side effects arising from booster vaccination using AstraZeneca vaccine were dominated by local side effects such as pain at the injection site on shoulder (56%), injection site soreness (56%), followed by systemic side effects like muscle aches throughout the body (28.5%), fever (27%), and headache (25.2%). The results of the independent t-test revealed a probability value of 0.001 (<0.05). This can be inferred that there are significant differences in local and systemic side effects. Thus, it can be concluded that local side effects are reported more often than systemic side effects.
Keywords: Booster, COVID-19, side-effects, vaccine
Keywords
Full Text:
PDF (Bahasa Indonesia)References
World Health Organization. COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm). COVID-19 vaccine explain [Internet]. 2021May:1–6. (diunduh 5 Juli 2022). Tersedia dari: https://www.who.int/publications/m/item/sinopharm-vero-cell-inactivated-covid-19-vaccine.
Baraniuk C. What do we know about China’s covid-19 vaccines? BMJ. 2021;373:59–60.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, dkk. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, dkk. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99– 111.
Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, dkk. Side effects reported by jordanian healthcare workers who received covid-19 vaccines. Vaccines. 2021;9(6):1–10.
Dzieciolowska S, Hamel D, Gadio S, Dionne M. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. Am J Infect Control. 2020;49(2021):1152-1157.
Weber DJ, Al-Tawfiq JA, Babcock HM, Bryant K, Drees M, Elshaboury R, dkk. Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel. Infect Control Hosp Epidemiol. 2022;43(1):3–11.
Mbunge E, Fashoto SG, Akinnuwesi B, Metfula A, Simelane S, Ndumiso N. Ethics for integrating emerging technologies to contain COVID-19 in Zimbabwe. Hum Behav Emerg Technol. 2021;3(5):876–90.
Megget K. Even covid-19 can’t kill the anti- vaccination movement. BMJ [Internet]. 2020 June;369:1–2. (diunduh 5 Juli 2022) Tersedia dari: http:// dx.doi.org/doi:10.1136/bmj.m2184.
Tafuri S, Martinelli D, Prato R, Germinario C. [From the struggle for freedom to the denial of evidence: history of the anti-vaccination movements in Europe]. Ann Ig [Internet]. 2011;23(2):93–9. (diunduh 5 Juli 2022) Tersedia dari: http://www. ncbi.nlm.nih.gov/pubmed/21770225.
Tequare MH, Abraha HE, Adhana MT, Tekle TH, Belayneh EK, Gebresilassie KB, dkk. Adverse events of Oxford/AstraZeneca’s COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. IJID Reg [Internet]. 2021 August;1:124–9. (diunduh 5 Juli 2022). Tersedia dari: https://doi.org/10.1016/j.ijregi.2021.10.013.
Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, dkk. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- research that is available on the COVID-19 resource centre - including this for unrestricted research re-use a. 2020 January:19–21. (diunduh 5 Juli 2022).
Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, dkk. Effectiveness of the Pfizer- BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:1-9.
Cabezas C, Coma E, Mora-Fernandez N, Li X, Martinez-Marcos M, Fina F, dkk. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and dea-9th with covid-19 in nursing homes and healthcare workers in Catalonia: Prospective cohort study. BMJ. 2021;374:1-8.
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, dkk. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.
Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, dkk. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022;13(1):1–11.
Cheng CJ, Lu CY, Chang YH, Sun Y, Chu HJ, Lee CY, dkk. Effectiveness of the who-authorized covid-19 vaccines: a rapid review of global reports till 30 June 2021. Vaccines. 2021;9(12):1–21.
Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. medRxiv [Internet]. 2021;2:2021.11.15.21266341. (diunduh 5 Juli 2022) Tersedia dari: https://www.medrxiv.org/cont ent/10.1101/2021.11.15.21266341v1%0Ahttps:// www.medrxiv.org/content/10.1101/2021.11.15.21 266341v1.abstract.
Furlong A, Deutsch J. A country-by-country guide to coronavirus vaccine booster plans. Politico. 2021;volume:1-28.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, dkk. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–76.
Parés-Badell O, Martínez-Gómez X, Pinós L, Borras-Bermejo B, Uriona S, Otero-Romero S, dkk. Local and systemic adverse reactions to mrna covid-19 vaccines comparing two vaccine types and occurrence of previous Covid-19 infection. Vaccines. 2021;9(12):3–11.
Krammer F. SARS-CoV-2 vaccines in development. Nature [Internet]. 2020;586(7830):516–27. Tersedia dari: http://dx.doi.org/10.1038/ s41586-020-2798-3.
Jespers V. Rapid review of the evidence on a Covid-19 booster dose after a primary vaccination schedule. 2021 August (diunduh 5 Juli 2022). Tersedia dari: https:// kce.fgov.be/en/rapid-review-of-the-evidence-on-a-covid-19-booster-dose-after-a-primary- vaccination-schedule
Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, dkk. Article prevalence and risk factors of coronavac side effects: an independent cross- sectional study among healthcare workers in turkey. J Clin Med. 2021;10(12):1–13.
Darraj MA, Al-mekhlafi HM. Prospective evaluation of side-effects following the first dose of Oxford/AstraZeneca COVID-19 Vaccine among healthcare workers in Saudi Arabia. MDPI.2022;10(223):1–14.
DOI: https://doi.org/10.29313/jiks.v5i1.10211
Refbacks
- There are currently no refbacks.
Jurnal Integrasi Kesehatan dan Sains is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.